Previous Page  2 / 827 Next Page
Show Menu
Previous Page 2 / 827 Next Page
Page Background


International Congress of Immunology 2016

Abstract Book

Oral Abstracts | Monday, 22 August 2016

30 Minute Oral | 08:30 - 10:15

B Cells

Novel aspects of B cell response to vaccination and viral


Batista,F. Gaya, M, Martinez, N.

Ragon Institute

B lymphocytes form an integral part of the immune system

via the production of specific antibodies and by establishing

immunological memory enabling a swift an effective response

to pathogenic assault. To fully understand the processes

whereby this is achieved, it is essential to gain a comprehensive

understanding of the events involved in B cell activation and

antibody production. This is initiated by the encounter with

and acquisition of cognate antigen by the B cell receptor

(BCR); processes occurring primarily in secondary lymph nodes

(SLOs) such as the lymph node (LN) and which are regulated by

complex systems. The functionality of these systems is strictly

dependent on maintaining the architecture of the SLOs. During

this talk I will describe how the LN structure enables the early

encounter of B cells with antigen. Antigenic properties such as

the size and nature of the pathogen affect the specialized lymph

n ode antigen delivery systems that exist in readiness to deliver

pathogen-derived antigen to B cells. This variability in the types

of encounter enables the most appropriate response for that

particular antigen to occur, giving the maximal protection to

the host. Lastly, the consequences of the disruption of the LN

architecture, and the help provided by other cells such as iNKTs,

on the immune response will also be described. Their critical role

in the immune response is evident following infection, which

causes a temporary disruption in the cellular organization of

lymphoid organs and lack of essential cytokines leading to a

reduction in immune responses.

Tolerance & Transplantation

Immunoregulation in Transplantation

Wood, K., Bushell, A., Harden, P., Issa, F., Hester, J.

University of Oxford

Immune regulation is fundamental to any immune response

to ensure that it is appropriate for the perceived threat to the

host. Strategies for the induction of specific unresponsiveness

to donor alloantigens currently under investigation in the clinic

takeadvantageof twoof themajormechanisms for the induction

of tolerance to self antigens – deletion and immunoregulation/


have demonstrated that human regulatory

T cells expanded ex vivo can protect human allografts (skin,

islets and vessels) from rejection. Treg migrate to the allograft

and function in situ. Donor alloantigen reactive Treg are more

effective on a per cell basis than polyclonal Treg. Together

with other leukocyte populations, including regulatory T cells,

B cells and macrophages as well as myeloid derived suppressor

cells and dendritic cells, Treg contribute to the regulation of

immune responses in vivo after organ transplantation. The

identification and characterisation of Treg that can control

immune responsiveness to alloantigens has opened up exciting

opportunities for new therapies in transplantation. Phase1/2a

clinical trials are in progress –

A new approach to GVHD based on biomarkers

Ferrara, J.

Icahn School of Medicine at Mount Sinai

Acute graft versus host disease (GVHD) is the major toxicity

of allogeneic bone marrow transplantation. Recent research

has identified and validated unexpected biomarkers that

predict outcomes. This session will review the use of large and

informative biorepositories to create biomarker signatures that

predict severe GVHD prior to its clinical onset and that can

guide preemptive GVHD therapy. This session will also review

mechanistic studies have illuminated unexpected interactions

between the innate and adaptive immune systems in the GI

tract that have led to both conceptual breakthroughs and the

discovery of novel therapeutic approaches.

Cancer Immunotherapy

Immunotherapy for persisting viral infection and associated


Frazer, I.


, Mattarollo, S.


,Leggatt, G.


, Wells, J.


, Tuong, K.


, Kuo, P.



Jazayeri, S.


, Lambert, P.


, Chandra, J.



The University of Queensland, Australia,


The University of

Madison, Wisconsin,


Admedus Immunotherapies

While vaccines have proven effective at preventing virus

infections, immunotherapy for persisting cancer associated

viral infections and their associated cancers has proven less

tractable. Using a model where a viral antigen, the E7 protein

of human papillomavirus (HPV)16, is expressed in grafted

mouse skin, we have determined mechanisms preventing

effective immunotherapy of persisting HPV infection. In this

model, the effector functions of vaccine induced cytotoxic T

cells are locally inhibited by multiple mechanisms initiated by

hyper-proliferative epithelium associated with HPV infection,

and mediated via inflammasome activation, IL-18 and IFNg.

Intra-dermal delivery of an E7 specific polynucleotide vaccine

encoding ubiquitin conjugated viral proteins can overcome

inhibition of effector T cell function in this model. A herpes

virus(HSV) glycoprotein D immunotherapy using the same

strategy has, in clinical trial, induced a cell mediated immune

responses,and is currently under evaluation in persistently HSV-

2 infected subjects.